Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial

NCT00268853 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00268853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
May 31, 2012
Enrollment
124 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large-cell lymphoma